Skip to main content
. 2018 Jun 1;9(42):26978–26979. doi: 10.18632/oncotarget.25605

Figure 7. Implication of p38 in the resistance to oxaliplatin.

Figure 7

(B to D). Cytotoxicity assays were performed with HT29-D4, Rox1 and Rox2 treated with oxaliplatin and incubated in the absence (Control) or in the presence of SB203580, a specific inhibitor of p38 (5 μM).